Adults with overweight or obesity who received once-weekly ecnoglutide, a novel GLP-1 receptor agonist, had superior and ...

VANQUISH-1 and VANQUISH-2 Studies to Evaluate Subcutaneous VK2735 in Obese Adults with and without Type 2 Diabetes SAN DIEGO, June 25, 2025 /PRNewswire/ -- Viking ...

New indication added for selection of patients for amyloid-directed therapiesQuantitative image analysis addedPrevious limitations of use removed BOSTON, July 1, 2025 /PRNewswire/ -- Life Molecular ...

DALLAS, June 20, 2025 It's only the first day of summer and record high temperatures are already being reported across much ...

The AHA says the heat and dehydration put significant stress on the heart. Certain heart medications can also heighten the ...

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report) has received an average recommendation of “Moderate Buy” from the ten ratings firms that are covering the stock, MarketBeat reports. One ...

Corbus Pharmaceuticals Holdings' financial position is stable for now, with about two years of cash runway. Click here to find out why CRBP stock is a Buy.

Alto Neuroscience’s phase 2 depression trial has missed its primary efficacy endpoint, as patients on the drug candidate fared no better on a measure of alertness and mood than their peers on placebo.

Transforming growth factor beta (TGFβ) is a cytokine that is secreted by various cell types, ... apoptosis and cellular homeostasis by binding to its receptor, the TGFβ type II receptor.

Equities researchers at Lifesci Capital issued their Q2 2025 EPS estimates for Cogent Biosciences in a research report issued to clients and investors on Monday, June 30th. Lifesci Capital analyst S.

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...